L3VLUP
ProSign in

LAB in the 13F filings

Standard Biotools Inc · CUSIP 34385P108

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2021Q3 2021
Quarter end
30 Sep 2021
the date the book describes
Filed
15 Nov 2021
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2021 and Q3 2021; 1 listed it in both
Shares listed
127,900
combined, among listed positions
Reported value
$843k
combined, at the quarter end

Managers listing LAB in Q3 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
PDT Partners LLC127,900$843k0.06%Trimmed-68,72815 Nov 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2021 to Q3 2021, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q3 2024 to 1 in Q2 2026

Tracked managers listing it, at least.

0246201620172018201920202021202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
LAB by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20151$6.5mn.a.n.a.
Q4 20151$8.6mn.a.n.a.
Q1 20162$9.9mn.a.n.a.
Q2 20163$10mn.a.n.a.
Q3 20162$6.7mn.a.n.a.
Q4 20162$6.1mn.a.n.a.
Q1 20171$100kn.a.n.a.
Q1 20181$873kn.a.n.a.
Q2 20182$2.0mn.a.n.a.
Q3 20184$41mn.a.n.a.
Q4 20184$60mn.a.n.a.
Q1 20196$101mn.a.n.a.
Q2 20195$89mn.a.n.a.
Q3 20193$9.5mn.a.n.a.
Q4 20191$5.9mn.a.n.a.
Q1 20202$4.3mn.a.n.a.
Q2 20201$5.3mn.a.n.a.
Q3 20205$51mn.a.n.a.
Q4 20204$13mn.a.n.a.
Q1 20211$2.2mn.a.n.a.
Q2 20211$1.2mn.a.n.a.
Q3 20211$843kn.a.n.a.
Q4 20211$585kn.a.n.a.
Q1 20242$194m20
Q2 20242$126m01
Q3 20242$130m01
Q4 20242$108m01
Q1 20252$67m10
Q2 20252$74m01
Q3 20252$80m01
Q4 20252$79m75
Q1 20261$54m84
Q2 20261$48m185

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

LAB and LLY →LAB and JNJ →LAB and VRTX →Choose a stock to compare with LAB →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own LAB, latest filings →Back to the 13F Explorer →